Reimbursement in France for first IVD to help diagnose Glut1 deficiency syndrome

METAglut1TM obtains universal national coverage by French National Health Insurance as of February 22, 2024 after approval by the French National Authority for Health.

A fine achievement for the collaborative work of several teams from l’AP-HP, l’IGMM Institut de Génétique Moléculaire de Montpellier (CNRS/Université de Montpellier) and Metafora-Biosystems .

METAglut1, a fast, reliable blood test, provides an early diagnosis of Glut1 deficiency syndrome, or De Vivo disease, a rare and disabling neurological condition.